Non-interventional study for recording the treatment and the influence on the treatment-specific quality of life with patients with hormone-refractory prostate cancer under a Docetaxel (Eurotere®) containing chemotherapy.

Non-interventional study for recording the treatment and the influence on the treatment-specific quality of life with patients with hormone-refractory prostate cancer under a Docetaxel (Eurotere®) containing chemotherapy. - ProQoLTere

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003069

Enrollment

500

Registered

2011-05-02

Start date

2011-07-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hormone Refractory Prostate Cancer C61

Interventions

Group 1: Routine treatment with Docetaxel, collection of data concerning quality of life at the beginning, after 3 and after 9 months, assessment of efficacy and safety.

Eligibility

Sex/Gender

Male

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Histologically confirmed hormone-refractory prostate cancer. Signed patient informed consent form.

Exclusion criteria

Exclusion criteria: Other malignant diseases in the past 5 years, Lack of compliance.

Design outcomes

Primary

Measure	Time frame
Quality of life by means of the validated Patient Oriented Prostate Cancer Utility Scale (PORPUS) at the beginning of the observation, after 3 months and after 9 months.	—

Secondary

Measure	Time frame
Impact of the form of the therapy (mono, combination, application frequency) on the course of the therapy, Impact of prior symptoms on the course of the therapy, Predictive criteria for an improvement of the quality of life, Collection of prognostic criteria, Association between tumor response and treatment specific quality of life, Evaluation of adverse drug reactions / events.	—

Countries

Germany

Contacts

Public ContactHeribert Stiegler

OnkoDataMed GmbH

heribert.stiegler@onkodatamed.de030 / 64 38 75 60

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026